Systolic dysfunction

Systolic dysfunction

WikiDoc Resources for Systolic dysfunction
Articles
Most recent articles on Systolic dysfunction Most cited articles on Systolic dysfunction Review articles on Systolic dysfunction Articles on Systolic dysfunction in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Systolic dysfunction Images of Systolic dysfunction Photos of Systolic dysfunction Podcasts & MP3s on Systolic dysfunction Videos on Systolic dysfunction
Evidence Based Medicine
Cochrane Collaboration on Systolic dysfunction Bandolier on Systolic dysfunction TRIP on Systolic dysfunction
Clinical Trials
Ongoing Trials on Systolic dysfunction at Clinical Trials.gov Trial results on Systolic dysfunction Clinical Trials on Systolic dysfunction at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Systolic dysfunction NICE Guidance on Systolic dysfunction NHS PRODIGY Guidance FDA on Systolic dysfunction CDC on Systolic dysfunction
Books
Books on Systolic dysfunction
News
Systolic dysfunction in the news Be alerted to news on Systolic dysfunction News trends on Systolic dysfunction
Commentary
Blogs on Systolic dysfunction
Definitions
Definitions of Systolic dysfunction
Patient Resources / Community
Patient resources on Systolic dysfunction Discussion groups on Systolic dysfunction Patient Handouts on Systolic dysfunction Directions to Hospitals Treating Systolic dysfunction Risk calculators and risk factors for Systolic dysfunction
Healthcare Provider Resources
Symptoms of Systolic dysfunction Causes & Risk Factors for Systolic dysfunction Diagnostic studies for Systolic dysfunction Treatment of Systolic dysfunction
Continuing Medical Education (CME)
CME Programs on Systolic dysfunction
International
Systolic dysfunction en Espanol Systolic dysfunction en Francais
Business
Systolic dysfunction in the Marketplace Patents on Systolic dysfunction
Experimental / Informatics
List of terms related to Systolic dysfunction

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Left ventricular systolic dysfunction is the condition where the left ventricle can only manage to eject less than 40% (occasionally less than 35%) of the blood in it, with each contraction. The term is used when the echocardiogram shows this but the patient isn’t in overt heart failure.

Treatment

Non-pharmacologic treatment

• Exercise
• Dietary changes
• Operative therapy: Surgery for underlying valvular heart diseases

Pharmacotherapy

For patients with systolic dysfunction (EF < 40%) who have no contraindications:

• ACE (angiotensin-converting enzyme) inhibitors for all patients.
• Beta blockers for all patients except those who are hemodynamically unstable, or those who have rest dyspnea with signs of congestion.
• Aldosterone antagonist (low dose) for patients with rest dyspnea or with a history of rest dyspnea or for symptomatic patients who have suffered a recent myocardial infarction.
• Isorbide dinitrates-hydralazine combination for symptomatic heart failure patients who are African-American.
• ARBs (angiotensin receptor blockers) as a substitute for patients intolerant of ACE inhibitors.
• Digoxin only for patients who remain symptomatic despite diuretics, ACE inhibitors and beta blockers or for those in atrial fibrillation.
• Diuretics for symptomatic patients to maintain appropriate fluid balance.

Device based therapy

• Implantable defibrillators considered for prophylaxis against sudden cardiac death in patients with EF ≤ 35%.
• Bi-ventricular pacemakers considered for patients requiring defibrillators who have symptomatic HF and QRS durations ≥ 120 msec.

ACC / AHA Guidelines- Recommendations for Cardiac Resynchronization Therapy in Patients With Severe Systolic Heart Failure (DO NOT EDIT)

“

Class I 1. For patients who have LVEF less than or equal to 35%, a QRS duration greater than or equal to 0.12 seconds, and sinus rhythm, CRT with or without an ICD is indicated for the treatment of NYHA functional Class III or ambulatory Class IV heart failure symptoms with optimal recommended medical therapy. (Level of Evidence: A) Class IIa 1. For patients who have LVEF less than or equal to 35%, a QRS duration greater than or equal to 0.12 seconds, and AF, CRT with or without an ICD is reasonable for the treatment of NYHA functional Class III or ambulatory Class IV heart failure symptoms on optimal recommended medical therapy. (Level of Evidence: B) 2. For patients with LVEF less than or equal to 35% with NYHA functional Class III or ambulatory Class IV symptoms who are receiving optimal recommended medical therapy and who have frequent dependence on ventricular pacing, CRT is reasonable. (Level of Evidence: C) Class IIb 1. For patients with LVEF less than or equal to 35% with NYHA functional Class I or II symptoms who are receiving optimal recommended medical therapy and who are undergoing implantation of a permanent pacemaker and/or ICD with anticipated frequent ventricular pacing, CRT may be considered. (Level of Evidence: C) Class III 1. CRT is not indicated for asymptomatic patients with reduced LVEF in the absence of other indications for pacing. (Level of Evidence: B) 2. CRT is not indicated for patients whose functional status and life expectancy are limited predominantly by chronic noncardiac conditions. (Level of Evidence: C)

”

Related Chapters

• Heart failure
• Diastolic dysfunction

Guideline Resource

• The ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities

Additional Readings

• Shekelle P, Rich M, Morton S, et al. Pharmacologic Management of Heart Failure and Left Ventricular Systolic Dysfunction: Effect in Female, Black, and Diabetic Patients, and Cost-Effectiveness. Evidence Report/Technology Assessment No. 82 (Prepared by the Southern California-RAND Evidence-based Practice Center under Contract No 290-97-0001). AHRQ Publication No. 03-E045. Rockville, MD: Agency for Healthcare Research and Quality. July 2003

• McAlister FA, Ezekowitz J, Dryden DM, Hooton N, Vandermeer B, Friesen C, Spooner C, Rowe BH. Cardiac Resynchronization Therapy and Implantable Cardiac Defibrillators in Left Ventricular Systolic Dysfunction. Evidence Report/Technology Assessment No. 152 (Prepared by the University of Alberta Evidence-based Practice Center under Contract No. 290-02-0023). AHRQ Publication No. 07-E009. Rockville, MD: Agency for Healthcare Research and Quality. June 2007.

References

Template:WikiDoc Sources